EU/3/19/2152 - orphan designation for treatment of Stargardt's disease

3-(3-(3,5-bis(trifluoromethyl)phenyl)-1h-pyrazol-1-yl)propanoic acid

Overview

On 24 April 2019, orphan designation (EU/3/19/2152) was granted by the European Commission to TMC Pharma (EU) Limited, Ireland, for 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-pyrazol-1-YL)propanoic acid (also known as STG‑001) for the treatment of Stargardt's disease.

What is Stargardt's disease?

Stargardt’s disease is a hereditary disorder of the eye that leads to progressive loss of sight. In the majority of cases Stargardt’s disease is caused by abnormalities in a gene called ABCA4. The ABCA4 gene is responsible for the production of a protein called ABCR that regulates the transport of substances in and out of some cells in the retina (the light-sensitive surface at the back of the eye). In patients with Stargardt’s disease, ABCR does not work properly. As a result, deposits known as lipofuscins, made of fats and proteins, build up inside the retina cells, which become damaged and eventually die.

Stargardt’s disease is a long-term debilitating disease, because the patient's sight becomes progressively worse and eventually leads to blindness.

What is the estimated number of patients affected by the condition?

At the time of designation, Stargardt's disease affected approximately 1 in 10,000 people in the European Union (EU). This was equivalent to a total of around 52,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 518,400,000 (Eurostat 2019).

What treatments are available?

At the time of designation, no satisfactory methods were authorised in the EU for the treatment of Stargardt's disease.

How is this medicine expected to work?

Vitamin A (retinol) is a key component of the toxic substances that build up in the retina of patients with Stargardt's disease. This vitamin is carried to the retina with the help of a protein called RBP4.

The medicine attaches to RBP4, stopping it from transporting vitamin A to the retina and thereby reducing the build-up of the toxic substances.

What is the stage of development of this medicine?

The effects of 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-pyrazol-1-YL)propanoic acid have been evaluated in experimental models.

At the time of submission of the application for orphan designation, no clinical trials with the medicine in patients with Stargardt's disease had been started.

At the time of submission, the medicine was not authorised anywhere in the EU for the treatment of Stargardt's disease or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000, the COMP adopted a positive opinion on 21 March 2019, recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/19/2152: Public summary of opinion on orphan designation: 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1h-pyrazol-1-yl)propanoic acid for the treatment of Stargardt's disease

Adopted Reference Number: EMADOC-628903358-740

Key facts

• Active substance:
  3-(3-(3,5-bis(trifluoromethyl)phenyl)-1h-pyrazol-1-yl)propanoic acid
• Intended use:
  Treatment of Stargardt's disease
• Orphan designation status:
  Withdrawn
• EU designation number:
  EU/3/19/2152
• Date of designation:
  24/04/2019
• Sponsor:

  TMC Pharma (EU) Limited; 7A Durands Court; 45 Parnell Street; Waterford; Co. Waterford; X91 P381; Ireland; Tel. + 353766705745; E-mail: [e-mail]

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.